Table 1 Eight potential cancer driver genes identified through analyzing cancer-specific mutations.
From: Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes
Gene | Full name | Molecular function | Cancer dependency | Expression and prognosis |
|---|---|---|---|---|
CEP57 | Centrosomal protein 57 | Centrosomal protein which may be required for microtubule attachment to centrosomes | Esophageal, gastric | Glioma (favorable) |
HNRNPL | Heterogeneous nuclear ribonucleoprotein LÂ | Splicing factor binding to exonic or intronic sites and acting as either an activator or repressor of exon inclusion | Gastric, pancreas, leukemia, endometrial | Renal cancer (unfavorable), pancreatic cancer (unfavorable), liver cancer (unfavorable) |
KLF5 | Kruppel Like Factor 5Â | Transcription factor that binds to GC box promoter elements | Colon | Pancreatic cancer (unfavorable) |
OXA1L | Oxidase (Cytochrome C) Assembly 1-Like | Essential for the activity and assembly of cytochrome oxidase | Ovarian, lung NSCLC | Renal cancer (favorable) |
PAFAH1B1 | Platelet activating factor acetylhydrolase 1b regulatory subunit 1 | Required for proper activation of Rho GTPases and actin polymerization at the leading edge of locomoting cerebellar neurons and postmigratory hippocampal neurons in response to calcium influx triggered via NMDA receptors | Gastric, ovarian, esophageal, colon, breast, leukemia, bladder, lung NSCLC, GBM, endometrial | Renal cancer (favorable) |
RBM39 | RNA-binding motif protein 39 | Transcriptional coactivator for steroid nuclear receptors ESR1/ER-alpha and ESR2/ER-beta, and JUN/AP-1 | Esophageal, gastric | Renal cancer (unfavorable) |
SYT13 | Synaptotagmin 13 | May be involved in transport vesicle docking to the plasma membrane | Colon, ovarian | Endometrial cancer (unfavorable) |
TFDP1 | Transcription factor Dp-1 | Can stimulate E2F-dependent transcription | Lung NSCLC, breast | Renal cancer (favorable), stomach cancer (favorable), liver cancer (unfavorable) |
